Hepatitis D results from a double viral infection. The evaluation of therapeutic goals requires consideration and targeting of two viral infections, adding complexity to the management of the HDV patient.
Therapy targets:

• the HDV
• the HBV
• both
THE LIFE CYCLE OF HDV

IMPLICATIONS FOR THERAPY
Attachment of HDV through HBsAg

Pre S1 sequence in L protein

= HBsAg
= HDV
HDV transferred to nucleus

- HBsAg
- HDV

nucleus
hepatocyte
HDV transferred to nucleus
Replication of HDV-RNA

HOST RNA polymerase II, I, III

+ = genomic HDV-RNA

- = antigenomic HDV-RNA

Cell Ligase HDV Ribozyme?

HDV Ribozyme
Replication of HDV-RNA

- Host RNA polymerase II, I, III

Cell Ligase
HDV Ribozyme

HDV Ribozyme

- = genomic HDV-RNA

+ = antigenomic HDV-RNA
Assembly of HDV virions

- HBsAg
- HDV-RNA

- hepatocyte
- nucleus
Assembly of HDV virions

- HBsAg
- HDV

- Hepatocyte
- Nucleus
- Virion assembly
Assembly of HDV virions

- HBsAg
- HDV

Virion assembly

hepatocyte

nucleus
HDV therapy problems

• HBV required only to provide the HBsAg capsid

• replication of HDV independent from HBV replication (i.e. from HBV-DNA levels)

• NO OWN REPLICATION FUNCTION OF HDV to be targeted by antivirals
HDV therapy

problems

HDV-RNA: not standardized, need for an international reference

Regional references:
- Paul Erlich (Germany)
- National Reference Center for Viral Hepatitis (France)
- Centers for Disease Control (USA)
- National Institute for Viral Disease (China)

IgM anti-HD: surrogate marker of disease activity
HDV: Antiviral Therapy
Drugs Evaluated for the Treatment of Chronic Hepatitis D

- Thymosin
- Ribavirin
- Lamivudine
- Famciclovir
- Adefovir
- Entecavir

No Efficacy

- IFN/Peg IFN

Limited Efficacy
Therapy of chronic hepatitis D with Peg-IFN

Sustained virologic response (SVR)

Monotherapy

- Peg-IFN-α2b 12m: 43%
- Peg-IFN-α2b 18m: 25%
- Peg-IFN-α2b 52w: 25%
- Peg-IFN-α2a 12m: 31%

Patients n°: 14

Combination

- Peg-IFN-α2a + Adefovir 12m: 26%
- Peg-IFN-α2b + RBV 18m: 18%

Patients n°: 31

m = months, w = weeks, P = Peg-IFN, RBV = ribavirin
HDV therapy problems

- small series of patients
- different designs and protocols
- ↓ ALT vs clearance HDV-RNA not always consistent
- clearance of HDV-RNA vs histology not always consistent
- no advantage to treat up to 24 vs 12 months in controlled series
Therapy – conclusions

The current recommendation is pegylated Interferon-alfa weekly for 12 to 18 months

20%-25% of the patients respond; HDV may relapse as long as HBsAg is around

Only reliable end-point of therapy is the clearance of the HBsAg
The SVR paradigm does not apply to hepatitis D (as long as HBsAg persists)

In the HBsAg setting, HDV may remain infectious at $10^{-11}$ serum dilutions, i.e. at titers far below the sensitivity threshold of current HDV-RNA assays ($10 \text{ cp/ml}$)
Possible factors predicting response to therapy

- HDV genotype: non 1 > 1
- Low HDV-RNA at baseline and decline during therapy
- Low HBsAg at baseline and decline during therapy?
Therapy of chronic hepatitis D

conclusions

• The current management of HDV patients is based on accepted common practice rather than on evidence from trials. Therefore therapy should be pragmatic and individualized.

• Therapy protocols should be determined on the clinical and virologic evolution during therapy.

• Therapy extended over 12 months may be of benefit in patients with partial responses. Therapy extended over years may be of benefit in the individual patient with rapidly advancing disease who responds to Peg-IFN but relapses on its withdrawal.
Therapeutic targets?

- **Attachment**
- **Nucleus**
- **Replication**
- **Virion Assembly**
- **Transfer**

**HBsAg**
- Blocked by farnesylation inhibitors
- Inactivated by Myrcludex

**HDV**
- Export

**= HBsAg**
**= HDV**
HDV: Therapy
Liver Transplantation
Liver transplantation for end-stage HDV disease

- Valid treatment, survival good
- Risk of graft reinfection distinctly lower than HBV
- HBIG with antivirals protect virtually every transplant
Latent HDV infection in liver

How long does it persist?
Up to 3 years in human liver grafts

Rizzetto, 2006; Moderacke, 2011

Even six weeks after initiating HDV infection, HBV can be used to superinfect, with assembly and release of infectious HDV

Lugehetmann, Hepatology, 2011
THE FUTURE

• Improved control (eradication?) of HDV through increased control of HBV

• Efficacious therapies in particular for residual difficult-to-treat disease

• HDV-RNA as a biological tool for developing therapeutic ribozymes